Association of ALOX5APgene single nucleotide polymorphisms and cerebral infarction in the Han population of northern China by Shuang-yan Zhang et al.
Zhang et al. BMC Medical Genetics 2012, 13:61
http://www.biomedcentral.com/1471-2350/13/61RESEARCH ARTICLE Open AccessAssociation of ALOX5AP gene single nucleotide
polymorphisms and cerebral infarction in the Han
population of northern China
Shuang-yan Zhang1, Mei-ling Xu1, Cui-e Zhang1*, Zheng-yi Qu1, Bin-bin Zhang1, Zu-yan Zheng2
and Li-ming Zhang3Abstract
Background: To explore the association of ALOX5AP single nucleotide polymorphisms (SNPs) and haplotype with
the occurrence of cerebral infarction in the Han population of northern China.
Methods: Blood samples were collected from 236 patients of Han ancestry with a history of cerebral infarction and
219 healthy subjects of Han ancestry with no history of cerebral infarction or cardiovascular disease. Applied
BiosystemsW TaqManW SNP Genotyping Assays for SNP genotyping were used to determine the genotypes of 7
ALOX5AP SNP alleles (rs4073259, rs4769874, rs9315050, rs9551963, rs10507391, rs9579646, and rs4147064).
Results: One SNP allele (A) of rs4073259 was significantly associated with development of cerebral infarction
(P= 0.049). In comparison to control groups, haplotype rs9315050&rs9551963 AAAC [OR (95% CI) =1.53 (1.02-2.29)],
and genotypes rs4147064 CT [OR (95% CI) =1.872 (1.082-3.241)], and rs9551963 AC [OR (95% CI) = 2.015 (1.165-
3.484)] increased the risk of cerebral infarction in patients with hypertension. Genotype rs9579646 GG [OR (95%
CI) = 2.926 (1.18-7.251)] increased the risk of, while rs4073259 GG [OR (95% CI) = 0.381 (0.157-0.922)] decreased the
risk of cerebral infarction in patients with diabetes.
Conclusion: These results suggest the ALOX5AP SNP A allele in rs4073259 and genotype rs9579646 GG, rs9551963
AC, and haplotype rs9315050 & rs9551963 AAAC were associated with an increased risk of ischemic stroke in the
Han population, while rs4073259 GG was associated with a decreased risk.
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Multiple studies have shown associations between var-
iants of the 5-lipoxygenase activating protein gene
(ALOX5AP) and risk for ischemic stroke and myocardial
infarction (MI) [1-9]. Two at-risk haplotypes (HapA and
HapB) for stroke had been identified in the ALOX5AP
gene [1,10]. The single nucleotide polymorphisms
(SNPs) associated with HapA are rs17222814,
rs10507391, rs4769874, and rs9551963, and those asso-
ciated with the HapB are rs17216473, rs10507391,
rs9315050, and rs17222842. Different studies, however,
reported conflicting results. The association of a 4-* Correspondence: Zhangcuie142@163.com
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reproduction in any medium, provided the ormarker SNP haplotype in ALOX5AP with approximately
2-times increased risk of ischemic stroke and myocardial
infarction was reported in an Icelandic population [1]. A
similar risk of stroke was found in Chinese males [5],
Japanese [8], and Europeans [2]. On the contrary, a
study found no association of ALOX5AP variants with
risk of MI or stroke in the United States (US) by Zee
et al. [6], whereas another study in the US by Kaushal
et al. [9] found a significant association with stroke
among whites, but no association among blacks. These
reports suggest that there might be variations between
the populations of different ancestries in the association
between ALOX5AP genetic variants and risk of stroke.
The purpose of this study was to study the possible as-
sociation of 7 variants of ALOX5AP, rs4073259,
rs4769874, rs9315050, rs9551963, rs10507391, rs9579646,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.






Age (y) 62.86 ± 11.34 50.36 ± 10.21 <0.001*
Triglycerides 1.75 ± 1.42 1.38 ± 0.93 <0.001*
Cholesterol 5.07 ± 1.16 5.00 ± 1.01 0.503
Male 125 (57.1) 145 (61.4) 0.390
Heart disease 39 (16.5) 0 <0.001*
Hypertension 88 (37.3) 0 <0.001*
Diabetes 54 (22.9) 0 <0.001*
Data are presented as mean ± standard deviation or number (percentage).
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Han ancestry in northern China.
Material and methods
Subjects
The subjects included in this study were patients diag-
nosed with cerebral infarction from three hospitals in-
cluding the Second Affiliated Hospital of Harbin
Medical University, the Forth Affiliated Clinical Hospital
of Harbin Medical University, and the First Affiliated
Hospital of Harbin Medical University from October
2004 to May 2010. All cases were diagnosed using the
Fourth edition of Cerebrovascular Disease Diagnostic
Standards [11]. Patients who had endocrine related dis-
eases, metabolic disorders, tumors, and cerebral
hemorrhage were excluded from this study. The control
group was composed of subjects who did not have cere-
brovascular diseases themselves, and no family history of
cerebrovascular diseases for a minimum of three genera-
tions. All the subjects in this study were from different
families of Han ethnicity whose families have lived in the
Northeastern part of China, including Heilongjiang, Jilin
and Liaoning, for more than 3 generations. This study
was approved by the Institutional Review Board of the
Fourth Affiliated Clinical Hospital of Harbin Medical
University and each participant provided written
informed consent.
DNA extraction and genotyping
DNA was extracted in a standard manner. Applied Bio-
systemsW TaqManW SNP Genotyping Assays were used
for SNP genotyping following the manufacturer’s
instructions. In brief, one to 20 ng template DNA dis-
solved in 2.25 μL volume each well was loaded into 384-
well plates for PCR. The reaction volume a total of 5 μL
included 2.5 μL TaqMan Universal PCR master Mix (2x)
and 0.25 μL 10× working stock of SNP genotyping assay
buffer. The PCR reaction conditions were 95 °C for
10 min followed by 60 cycles of 92 °C for 15 sec and
60 °C for 1 min in an ABI 9700 PCR instrument. The
genotyping data were collected by the ABI 9700 instru-
ment. During SNP genotyping, duplicates/positive/nega-
tive controls were used as previously described [12].
Of the 4 HapA SNPs (rs17222814, rs10507391,
rs4769874, and rs9551963), rs17222814 was not
selected because in our preliminary study this SNP was
shown to be almost monomorphic in the Chinese
population. Thus, we selected 3 SNPs rs10507391,
rs4769874, and rs9551963 from HapA for this study.
Of the 4 HapB SNPs (rs17216473, rs10507391,
rs9315050, and rs17222842), rs17222842 was excluded
because it is monomorphic in the Chinese population,
and rs17216473 was not selected because no significant
association with stroke was noted in a preliminarystudy. The SNPs rs9579646 and rs4147064 were
selected because they showed weak association with
stroke in Israeli [2] and middle European populations
[13], and rs4073259 was found to be associated with
stroke in a preliminary study [12].
Statistical analysis
Data are presented as mean± standard deviation or num-
ber (percentage). Hardy-Weinberg equilibrium (HWE)
testing was carried out for all 7 SNPs. Single markers in
association with the disease were assessed using χ2 tests
in Haploview Version 4.2 (Broad Institute, Cambridge,
MA, USA). Odds ratios (ORs) and 95% confidence inter-
vals (CIs) were calculated using logistic regression ana-
lysis. Statistical analysis was performed using by SPSS
version 15.0 statistical software (SPSS, Inc., Chicago, IL,
USA). A value of P< 0.05 was considered statistically
significant.
Results
Patient demographics and disease characteristics
The characteristics of ischemic stroke patients and con-
trols are summarized in Table 1. Patients with ischemic
stroke were older and had higher triglyceride level than
the controls (both P< 0.001). About 16.5% (n = 39),
37.3% (n = 88), and 22.9% (n = 54) of patients with ische-
mic stroke had also heart disease, hypertension or dia-
betes, respectively, while no control had these diseases
(All P< 0.001). Cholesterol levels and gender distribu-
tion were not different between the groups.
rs9579646/SG13S106 G 211 (48) 258(55) 0.0504
Univariate analysis of SNP distribution between ischemic
stroke patients and controls
The allele distribution of 7 SNPs of ALOX5AP was sum-
marized in Table 2. Only the frequency of rs4073259
SNP allele A was significantly different between ischemic
stroke patients and the controls (48% vs 54%,
P = 0.049). The frequency of rs9579646 allele G had a
marginal p value between the two groups (48% vs 55%,
P=0.0504).
Table 2 The association of ALOX5AP SNP allele with ischemic stroke in northern Han Chinese
# Public Name/SNP Name Allele Control Group (n=219) Case Group (n=236) P
1 rs4147064/SG13S137 T 148 (34) 186 (39) 0.0882
C 288 (66) 286 (61)
2 rs9579646/SG13S106 G 211 (48) 258 (55) 0.0504
A 227 (52) 214 (45)
3 rs4073259/SG13S100 A 208 (48) 255 (54) 0.0487
G 230 (53) 217 (46)
4 rs10507391/SG13S114 T 269 (62) 304 (64) 0.3979
A 167 (38) 168 (36)
5 rs4769874/SG13S89 G 429 (98) 464 (98) 0.6887
A 9 (2) 8 (2)
6 rs9315050/SG13S41 A 429 (98) 464 (98) 0.6887
G 9 (2) 8 (2)
7 rs9551963/SG13S32 C 147 (34) 188 (4) 0.0564
A 289 (66) 284 (60)
Data are presented as numbers (percentages).
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the ischemic stroke and the control groups is calculated
(Table 3). Individuals with a genotype of rs9551963 AC or
a genotype of rs9579646 GG had higher risks of develop-
ing a cerebral infarction than individuals with genotype
rs9551963 AA or genotype rs9579646 AA (OR=1.50
(1.01-2.24), P=0.046, OR=1.73 (1.01-2.97), P= 0.047,Table 3 Genotype distribution in the stroke and control grou
# Public Name Genotype Control Group (n=21
1 rs4147064 CC 97 (44)
CT 94 (43)
TT 27 (12)
2 rs9579646 AA 55 (25)
AG 117 (53)
GG 47 (21)
3 rs4073259 AA 45 (21)
AG 118 (54)
GG 56 (26)
4 rs10507391 AA 31 (14)
AT 105 (48)
TT 82 (38)
5 rs4769874 AG 9 (4)
GG 210 (96)
6 rs9315050 AA 210 (96)
AG 9 (4)
7 rs9551963 AA 99 (45)
AC 91 (42)
CC 28 (13)
Data are presented as numbers (percentages) or odds ratio (OR) with 95% confiden
*Significant difference between control and case groups (P< 0.05).respectively), But individuals with a genotype of GG in the
rs4073259 SNP had a lower risk (0.57-fold) of developing
a cerebral infarction than individuals with the AA geno-
type (95% CI 0.33-0.98, P = 0.044).
For further analysis, a comparison of genotype distribu-
tion between the control group and case subgroups strati-
fied into heart disease (n= 39), hypertension (n= 88), andps
9) Case Group (n=236) OR (95% CI) P
85 (36) Ref –
116 (49) 1.41 (0.95-2.10) 0.092
35 (15) 1.48 (0.83-2.64) 0.186
46 (19) Ref –
122 (52) 1.26 (0.79-2.01) 0.336
68 (29) 1.73 (1.01-2.97) 0.047*
66 (28) Ref –
123 (52) 0.72 (0.45-1.13) 0.152
47 (20) 0.57 (0.33-0.98) 0.044*
28 (12) Ref –
112 (47) 1.18 (0.66-2.10) 0.571
96 (41) 1.30 (0.72-2.34) 0.389
8 (3) Ref –
228 (97) 1.09 (0.40-2.95) 0.872
228 (97) Ref –
8 (3) 0.92 (0.34-2.50) 0.872
84 (36) Ref –
116 (49) 1.50 (1.01-2.24) 0.046*
36 (15) 1.52 (0.85-2.69) 0.155
ce interval (CI).






Heart disease (n=39) Hypertension (n=88) Diabetes (n=54)
OR (95% CI) P OR (95% CI) P OR (95% CI) P
1 rs4147064 CC 97 (44%) 1 1 1
CT 94 (43%) 1.096 (0.523-2.296) 0.8072 1.872 (1.082-3.241) 0.0251* 1.548 (0.8-2.995) 0.195
TT 27 (12%) 1.347 (0.481-3.776) 0.5707 1.596 (0.715-3.562) 0.2534 1.796 (0.725-4.448) 0.2055
2 rs9579646 AA 55 (25%) 1 1 1
AG 117 (53%) 1.067 (0.437-2.604) 0.8871 1.171 (0.612-2.24) 0.6326 1.541 (0.655-3.623) 0.3215
GG 47 (21%) 1.902 (0.726-4.981) 0.1908 1.996 (0.977-4.077) 0.0578 2.926 (1.18-7.251) 0.0204*
3 rs4073259 AA 45 (21%) 1 1 1
AG 118 (54%) 0.533 (0.241-1.176) 0.1189 0.591 (0.328-1.062) 0.0787 0.526 (0.266-1.043) 0.066
GG 56 (26%) 0.495 (0.189-1.297) 0.1523 0.488 (0.238-1.001) 0.0504 0.381 (0.157-0.922) 0.0324*
4 rs10507391 AA 31 (14%) 1 1 1
AT 105 (48%) 1.475 (0.469-4.64) 0.5058 0.84 (0.398-1.776) 0.6485 1.771 (0.571-5.493) 0.3221
TT 82 (38%) 1.417 (0.436-4.601) 0.5619 1.105 (0.52-2.347) 0.7949 2.457 (0.793-7.614) 0.1192
5 rs4769874 AG 9 (4%) 1 1 1
GG 210 (96%) 0.704 (0.144-3.448) 0.6655 1.079 (0.28-4.166) 0.9118 0.647 (0.166-2.526) 0.5312
6 rs9315050 AA 210 (96%) 1 1 1
AG 9 (4%) 1.42 (0.29-6.949) 0.6655 0.926 (0.24-3.576) 0.9118 1.545 (0.396-6.029) 0.5312
7 rs9551963 AA 99 (45%) 1 1 1
AC 91 (42%) 1.156 (0.552-2.422) 0.701 2.015 (1.165-3.484) 0.0122* 1.792 (0.92-3.489) 0.0863
CC 28 (13%) 1.326 (0.474-3.706) 0.5906 1.44 (0.636-3.261) 0.3813 1.872 (0.753-4.652) 0.1771
Data are presented as numbers (percentages) or odds ratios (OR) with 95% confidence interval (CI).
*Significant differences between controls and case subgroups (P< 0.05).
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controls, rs4147064 genotype CT [OR (95%CI) =1.872
(1.082-3.241)] and rs9551963 genotype AC [OR (95% CI=
2.015 (1.165-3.484)] were positively significantly associated
with cerebral infarction in patients with hypertension.
Genotype rs9579646 GG [OR (95% CI)= 2.926 (1.18-
7.251)] was positively significantly associated with, while
genotype rs4073259 GG [OR (95% CI)= 0.381 (0.157-
0.922)] was negatively significantly associated with cerebral
infarction in patients with diabetes.Analysis of haplotype distribution between ischemic
stroke patients and controls
The haplotype distribution in the stroke and control
groups are shown in Table 5. Patients with haplotype
rs9315050&rs9551963 AAAC had a higher risk to have
ischemic stroke than haplotype rs9315050&rs9551963
AAAA (OR= 1.53 (1.02-2.29), P= 0.041).
We further did linkage disequllibrium analysis and
found significant linkage between rs9315050 vs.
rs9551963, rs4073259 vs. rs10507391, and rs9579646 vs.
rs4147064 (D’= 1.0, D’= 0.911, and D’= 0.376, respect-
ively, Figure 1).Discussion
Our findings indicate that the A allele in rs4073259 is
markedly increased in cerebral infarction patients in
comparison to control subjects of Han ancestry in
northern China. Genotype rs9579646 GG and rs9551963
AC were positively, while rs4073259 GG was negatively
associated with cerebral infarction. Haplotypes
rs9315050 & rs9551963 AAAC were positively asso-
ciated with cerebral infarction. Furthermore, genotypes
rs4147064 CT and rs9551963 AC were associated with
cerebral infarction in patients with hypertension, while
rs9579646 GG and rs4073259 GG were associated with
cerebral infarction in patients with diabetes. The find-
ings suggest that SNP rs4073259 of the ALOX5AP gene
is associated with developing cerebral infarction in this
cohort, although the possibility that it is a functional
variant cannot be ruled out. Although we found no
marked difference in the frequency of alleles of other
ALOX5AP SNPs tested between the control and case
groups studied, we found significant differences of geno-
type frequency of other ALOX5AP SNPs between the
control and case subjects, suggesting that they might
play a role in the pathogenesis of cerebral infarction in
the Han population of northern China.
Table 5 Haplotype distribution in the stroke and control groups
Public Name Haplotype Control Groups (n=219) Case Groups (n=236) OR (95% CI) P
rs4147064 & rs9579646 CCAA 36 (17%) 26 (11%) Ref –
CCAG 50 (23%) 40 (17%) 1.11 (0.58-2.13) 0.759
CCGG 11 (5%) 19 (8%) 2.39 (0.98-5.87) 0.057
CTAA 15 (7%) 20 (8%) 1.85 (0.80-4.27) 0.152
CTAG 53 (24%) 64 (27%) 1.67 (0.90-3.12) 0.105
CTGG 26 (12%) 32 (14%) 1.70 (0.83-3.51) 0.148
TTAA 4 (2%) 0 (0%) – –
TTAG 13 (6%) 18 (8%) 1.92 (0.80-4.59) 0.144
TTGG 10 (5%) 17 (7%) 2.35 (0.93-5.97) 0.071
rs4073259 & rs10507391 AAAT 6 (3%) 2 (1%) Ref –
AATT 39 (18%) 64 (27%) 4.92 (0.95-25.61) 0.058
AGAA 2 (1%) 3 (1%) 4.50 (0.41-49.63) 0.219
AGAT 75 (34%) 90 (38%) 3.60 (0.71-18.36) 0.123
AGTT 40 (18%) 30 (13%) 2.25 (0.42-11.94) 0.341
GGAA 29 (13%) 25 (11%) 2.59 (0.48-13.98) 0.27
GGAT 24 (11%) 20 (8%) 2.50 (0.45-13.78) 0.293
GGTT 3 (1%) 2 (1%) 2.00 (0.18-22.06) 0.571
rs9315050 & rs9551963 AAAA 99 (45%) 84 (36%) Ref –
AAAC 85 (39%) 110 (47%) 1.53 (1.02-2.29) 0.041*
AACC 26 (12%) 34 (14%) 1.54 (0.86-2.77) 0.149
AGAC 6 (3)% 6 (3%) 1.18 (0.37-3.79) 0.783
AGCC 2 (1%) 2 (1%) 1.18 (0.16-8.55) 0.871
Data are presented as numbers (percentages) or odds ratios (OR) with 95% confidence interval (CI).
*Significant differences between control and case groups (P< 0.05).
Figure 1 Analysis of haplotype distribution between ischemic
stroke patients and controls. Linkage was found to be significant
between rs9315050 vs. rs9551963, rs4073259 vs. rs10507391, and
rs9579646 vs. rs4147064 (D’= 1.0, D’= 0.911, and D’= 0.376,
respectively).
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domains associated with cardiovascular and cerebrovas-
cular diseases which locate at 13p12-13 [1-3,10,14]. The
ALOX5AP gene is located at bands 2 and 3 of region 1
of the long arm of chromosome 13, and encodes 5-
lipoxygenase activating protein (FLAP) which regulates
the synthesis of leukotrienes [15]. An increase in the
production of leukotrienes and resulting inflammatory
changes in local blood vessels may be associated with
development of atherosclerosis [4,16-19]. Whether the
rs4073259 SNP alters FLAP warrants further study.
The association between the genetic polymorphism of
ALOX5AP and the occurrence of cerebral infarction has
been previously reported, but discrepancies between
studies carried out in different populations have been
noted. For example, Kaushal et al. [9] found that
rs957646 and rs769874 were significantly associated with
stroke in whites in the US, but no association was found
in blacks. Another US study by Zee et al. [6] found no
association of HapA or Hap B with stroke. Meschia
et al. [4] found no association of ALOX5AP variants and
ischemic stroke in a US population, Zhang et al. [5]
reported the ALOX5AP variant SG13S114T/A was
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males, and Linsel-Nitschke et al. [20] found HapB was
associated with an increased risk of myocardial infarc-
tion in a German population. Ji et al. [21] in a recent
study reported that the −581_582 Ins A polymorphism
in ALOX5AP might be a genetic risk factor for ischemic
stroke in the Chinese Han population. The lack of
consistency in available studies also suggests a limit of
the analytical methodologies used in these studies, the
population association test. A better refined method-
ology, such as the Family base association test (FBAT),
may be needed to provide consistent results [22].
Zintaras et al. [13] performed a meta-analysis in 2009
including all studies of ALOX5AP genotyping (5,194
stroke cases and 4,566 controls). The authors found sig-
nificant heterogeneity among studies (PQ=0.03,
I2 = 63%), a non-significant association between the
HapA and stroke risk (random-effects [RE] OR= 1.13,
95% CI 0.88-1.45), and no association of HapB with
stroke risk (RE OR= 1.03, 95% CI 0.77-1.37). They also
reported that the SG13S114, SG13S89, SG13S25,
SG13S32, SG13S35, and SG13S42 polymorphisms were
not associated with stroke. The authors concluded that
to date, the cumulated evidence did not support an asso-
ciation of ALOX5AP variants and risk of stroke, though
they cautioned that the conclusion was based on a rela-
tively small number of studies.
The primary limitation of this study is the relatively
low case number, especially in stratification based on
genotypes. Further study with a larger population is
required to confirm the findings. In addition, we did not
study SNPs from other susceptible genes, e.g., phospho-
diesterase 4D (PDE4D) in which some of the SNPs have
been shown to be associated with the development of
cerebral infarction [4].Conclusions
In summary, our results indicate the ALOX5AP SNP A
allele in rs4073259, genotype rs9579646 GG, rs9551963
AC, and haplotype rs9315050&rs9551963 AAAC were
associated with an increased risk of ischemic stroke in
the Han population, while rs4073259 GG was asso-
ciated with a decreased risk. Genotype rs4147064 CT
and rs9551963 AC were positively significantly asso-
ciated with cerebral infarction in patients with hyper-
tension while genotype rs9579646 GG was positively
significantly associated with, while genotype rs4073259
GG was negatively significantly associated with, cerebral
infarction in patients with diabetes. However, more
studies with large sample size are needed to detect the
extended haplotype, and further confirm whether other
SNPs of the ALOX5AP gene are associated with cere-
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